Investment firms like Citadel and Millennium recently bought Pfizer stock, despite its underperformance. With potential growth catalysts like oncology acquisitions and weight loss medications, investing in Pfizer could be a strategic move amidst low market expectations. However, caution and research are advised before making any investment decisions.